Because chronic non-healing wounds represent a major driver of carcinogenesis in RDEB, therapeutic strategies aimed at restoring COL7A1 function—such as gene or cell-based therapies—may improve wound closure, reduce persistent inflammation, and thereby decrease long-term cSCC risk. Here, COL7A1 is linked to recessive dystrophic epidermolysis bullosa.